CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

Core Insights - CorMedix Inc. has engaged WSI PBG to promote its product DefenCath to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities, aiming to enhance access for approximately 40,000 veterans with end-stage renal disease [1][2] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases, with its lead product DefenCath (taurolidine and heparin) approved by the FDA on November 15, 2023 [3] - The company launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024, and plans to commence clinical studies in adult Total Parenteral Nutrition patients and pediatric hemodialysis patient populations in 2025 [3] Collaboration Details - The collaboration with WSI PBG leverages their expertise in navigating the VA and federal facilities, focusing on access, procurement processes, and regulations to meet the unique needs of federal healthcare systems [2] - Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, highlighting WSI PBG's understanding of the federal healthcare landscape to improve access to DefenCath for veterans and other beneficiaries [3]